Biotech Drugs' Generic Future Debated
478185
With complicated and costly "biologics"  increasingly seen as the wave of the pharmaceutical future, health care experts warn that they will drive the nation's fast-growing bill for drugs far higher.
760357
Biotech funds differ in their make-up, performance, and promise.
738382
The drug maker is poised to speed past its rivals.
757415
The future will bring generic competition for Lipitor's lucrative base of customers.
66555
WASHINGTON - The bill Congress is soon expected to pass giving regulators more authority over pharmaceutical companies is most significant to biotech drug makers and their would-be generic rivals because of what was left out.
641201
A preview of some of the biopharmas presenting at the American Society of Clinical Oncology conference.
566909
The FDA decides to debate the company's lead drug.
732711
Democrats Hillary Rodham Clinton of  New York and Henry Waxman of California will introduce  legislation on Wednesday that would give the Food and Drug  Administration the legal authority to approve cheaper, generic  versions of biotech drugs known as biologics, the lawmakers  said.
120253
The Food and Drug Administration would have a legal path to approve cheaper, generic copies of biotech medicines under legislation in Congress.
511170
Now might be a great time to load up on cutting-edge drugmakers.
587421
Investors kept their eye on makers of generic pharmaceuticals Monday with news that Mylan Laboratories Inc. received Food and Drug Administration approval to market a generic version of a Novartis AG hypertension
274301
OTTAWA (CP) - Admitting that drug patent regulations are unclear and subject to abuse, Ottawa is returning the rules governing competition between brand-name and generic drug makers.
226441
Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch.
509369
The storm lashing big pharmaceutical companies over safety concerns about pain treatments such as Celebrex and Vioxx may actually blow some good in the direction of biotech stocks.
482126
J&J already has generic competition for its new drug.
169384
The US Food and Drug Administration is pushing for an expanded review of MDS Pharma&#39;s generic drug studies at its Montreal laboratories, and has requested a meeting with the company to discuss its concerns.
193614
The $73.5 billion global biotech business may soon have to grapple with a discovery that calls into question the scientific principles on which it was founded.